Arcutis Biotherapeutics (ARQT) announced the FDA acceptance of a supplemental New Drug Application, sNDA, for ZORYVE cream 0.3%, a once-daily, advanced targeted topical phosphodiesterase-4 inhibitor, to expand the indication for the topical treatment of plaque psoriasis to include children 2 to 5 years old. The FDA has set a PDUFA target action date of June 29, 2026, for this application.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics completes enrollment in INTEGUMENT-INFANT Phase 2 study
- Arcutis Biotherapeutics announces data from Phase 2 study of ZORYVE published
- Arcutis partners with Tori Spelling, Stella McDermott for campaign
- Arcutis Biotherapeutics announces commercial launch of ZORYVE cream
- Arcutis Biotherapeutics price target raised to $29 from $19 at Goldman Sachs